 |
市場調查報告書
商品編碼
2075953
思覺失調症治療市場：依療法、給藥途徑、患者特徵和地區分類Schizophrenia Therapeutic Market, By Therapy Type, By Administration Route, By Patient Demographics, By Geography |
||||||
價格
簡介目錄
2026年思覺失調症治療市場規模估計為78億美元，預計2033年將達到124億美元。預計2026年至2033年，該市場將以8.3%的複合年成長率成長。
| 報告範圍 | 報告詳情 | ||
|---|---|---|---|
| 基準年： | 2025 | 2026年市場規模： | 78億美元 |
| 歷史數據時期： | 2020年至2024年 | 預測期： | 2026年至2033年 |
| 2026年至2033年預測期間的複合年成長率： | 8.30% | 2033年市場規模預測： | 124億美元 |
全球思覺失調症市場涵蓋非典型抗精神病藥物、典型抗精神病藥物和輔助性治療等治療類別，並提供多種劑型，包括口服片劑、長效注射劑（LAI）和經皮製劑。這些產品廣泛應用於成人、青少年和老年人群，有助於提高療效、表現和可靠性。這些領域應用範圍的擴大以及持續的產品創新，將繼續推動市場成長。
市場動態：
關鍵應用領域需求的成長、對效率和性能日益重視以及持續的產品創新，預計將是推動全球思覺失調症治療市場成長的主要因素。成人和青少年群體接受度的提高以及對先進解決方案投資的增加，也進一步促進了市場擴張。
例如，各公司正日益開發專門用於口服藥片及相關應用的產品。此外，持續的研發投入和新技術的整合預計將在預測期內為市場參與者創造新的成長機會。
本研究的主要特點：
- 本研究揭示了各個細分市場的潛在商機，並為該市場說明了一個具有吸引力的投資提案矩陣。
- 此外，本研究還深入分析了市場促進因素、限制因素、機會、新產品發布和批准、市場趨勢、區域展望以及主要參與者採取的競爭策略。
- 本研究根據公司概況、產品系列、主要亮點、財務表現和策略等參數，介紹了全球思覺失調症治療市場主要公司的概況。
- 本報告提供的見解將使企業行銷負責人和經營團隊能夠就未來的產品發布、產品升級、市場擴張和行銷策略做出明智的決策。
- 這份《全球思覺失調症治療市場報告》旨在為該行業的各種相關人員提供服務，包括投資者、供應商、產品製造商、經銷商、新參與企業和金融分析師。
- 透過分析全球思覺失調症治療市場中使用的各種策略矩陣，相關人員將能夠做出更順利的決策。
目錄
第1章：研究目標與前提條件
- 分析目的
- 先決條件
- 簡稱
第2章 市場概覽
- 報告說明
- 市場定義和範圍
- 執行摘要
- Coherent Opportunity Map（COM）
第3章：市場動態、監管與趨勢分析
- 市場動態
- 促進因素
- 抑制因子
- 市場機遇
- 影響分析
- 近期產品發布
- 流行病學
- 併購和合作
- 監管趨勢
- 主要進展
- PEST分析
- 夥伴關係方案
- 品牌和定價分析
- 銷售代理情況
- 波特的分析
- 技術進步
- 主要進展
- 市場趨勢
- 前景
- 按銷售收入排名的主要公司
第4章：思覺失調症治療市場：依治療類型分類，2026-2033年
- 非典型抗精神病藥物
- 典型抗精神病藥物
- 輔助性治療
- 心理社會干預
- 其他
第5章：思覺失調症治療市場：依給藥途徑分類，2026-2033年
- 口服錠劑
- 長效注射藥物（LAI）
- 經皮吸收
- 其他
第6章思覺失調症治療市場：依患者特徵分類，2026-2033年
- 成人
- 青春期
- 老年人
- 其他
第7章：思覺失調症治療市場：依地區分類，2026-2033年
- 北美洲
- 美國
- 加拿大
- 拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
- 其他拉丁美洲國家
- 歐洲
- 英國
- 德國
- 義大利
- 法國
- 西班牙
- 俄羅斯
- 比荷盧經濟聯盟
- 丹麥
- 挪威
- 瑞典
- 其他歐洲國家
- 亞太地區
- 中國
- 台灣
- 印度
- 日本
- 印尼
- 馬來西亞
- 菲律賓
- 新加坡
- 澳洲
- 韓國
- 其他亞太國家
- 中東和非洲
- 巴林
- 科威特
- 阿曼
- 卡達
- 沙烏地阿拉伯
- UAE
- 以色列
- 南非
- 北非
- 中非
- 其他中東國家
第1章 競爭情勢
- Pfizer Inc.
- Otsuka Pharmaceutical Co., Ltd.
- Johnson & Johnson
- Sunovion Pharmaceuticals Inc.
- Novartis AG
- H. Lundbeck A/S
- Recordati SpA
- Mylan NV
- Alkermes plc
- Takeda Pharmaceutical Company Limited.
- Acadia Pharmaceuticals Inc.
第2章
- 調查方法
- 關於本公司
簡介目錄
Product Code: CMI2468
Schizophrenia Therapeutic Market is estimated to be valued at USD 7.80 billion in 2026 and is expected to reach USD 12.4 billion by 2033, growing at a compound annual growth rate (CAGR) of 8.3% from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 7.80 billion |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 8.30% | 2033 Value Projection: | USD 12.4 billion |
The global schizophrenia therapeutic market comprises therapy type categories such as Atypical Antipsychotics, Typical Antipsychotics, and Adjunctive Therapies, serving applications including Oral Tablets, Long-Acting Injectables(LAIs), and Transdermal. These offerings are adopted across Adult, Adolescent, and Geriatric and other areas, where they support improved efficiency, performance, and reliability. Growing adoption across these segments, combined with ongoing product innovation, continues to support expansion of the market.
Market Dynamics:
Rising demand across key application areas, increasing emphasis on efficiency and performance, and continued product innovation are major factors expected to drive growth of the global schizophrenia therapeutic market. Expanding adoption among Adult, and Adolescent and growing investment in advanced solutions are further supporting market expansion.
For instance, providers are increasingly developing offerings tailored to Oral Tablets and related applications. Moreover, ongoing research and development, along with the integration of new technologies, is expected to create new growth opportunities for market players over the forecast period.
Key features of the study:
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
- It profiles key players in the global schizophrenia therapeutic market based on the following parameters such as company highlights, products portfolio, key highlights, financial performance, and strategies.
- Key companies covered as a part of this study include Pfizer Inc., Johnson & Johnson, Otsuka Pharmaceutical Co, Ltd., Novartis AG, Sunovion Pharmaceuticals Inc., H. Lundbeck A/S, Recordati S.p.A., Mylan N.V., Alkermes plc, Takeda Pharmaceutical Company Limited, and Acadia Pharmaceuticals Inc, among others.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
- The global schizophrenia therapeutic market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global schizophrenia therapeutic market.
Detailed Segmentation:
- Global Schizophrenia Therapeutic Market, By Therapy Type (Revenue, USD Bn, 2021 - 2033)
- Atypical Antipsychotics
- Typical Antipsychotics
- Adjunctive Therapies
- Psychosocial Interventions
- Others
- Global Schizophrenia Therapeutic Market, By Administration Route (Revenue, USD Bn, 2021 - 2033)
- Oral Tablets
- Long-Acting Injectables(LAIs)
- Transdermal
- Others
- Global Schizophrenia Therapeutic Market, By Patient Demographics (Revenue, USD Bn, 2021 - 2033)
- Adult
- Adolescent
- Geriatric
- andOthers
- Regional Insights (Revenue, USD Bn, 2021 - 2033)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
- Company Profiles:
- Pfizer Inc.*
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Developments/Updates
- Strategies
- Johnson & Johnson
- Otsuka Pharmaceutical Co, Ltd.
- Novartis AG
- Sunovion Pharmaceuticals Inc.
- H. Lundbeck A/S
- Recordati S.p.A.
- Mylan N.V.
- Alkermes plc
- Takeda Pharmaceutical Company Limited
- Acadia Pharmaceuticals Inc
"*" marked represents similar segmentation in other categories in the respective section.
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Preview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snapshot, By Therapy Type
- Market Snapshot, By Administration Route
- Market Snapshot, By Patient Demographics
- Market Snapshot, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Impact Analysis
- Recent Product Launches
- Epidemiology
- Merger, Acquisition, and Collaboration
- Regulatory Scenario
- Key Developments
- PEST Analysis
- Partnership Scenario
- Brand and Pricing Analysis
- Distributors Landscape
- Porters Analysis
- Technological Advancements
- Key Developments
- Market Trend
- Future Prospective
- Top Market Players by Revenue
4. Schizophrenia Therapeutic Market By Therapy Type, 2026-2033, (US$ Billion)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022-2033
- Segment Trends
- Atypical Antipsychotics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Billion)
- Typical Antipsychotics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Billion)
- Adjunctive Therapies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Billion)
- Psychosocial Interventions
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Billion)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Billion)
5. Schizophrenia Therapeutic Market By Administration Route, 2026 - 2033, (US$ Billion)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022-2033
- Segment Trends
- Oral Tablets
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Billion)
- Long-Acting Injectables (LAIs)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Billion)
- Transdermal
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Billion)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Billion)
6. Schizophrenia Therapeutic Market By Patient Demographics, 2026 - 2033, (US$ Billion)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022-2033
- Segment Trends
- Adult
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Billion)
- Adolescent
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Billion)
- Geriatric
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Billion)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Billion)
7. Schizophrenia Therapeutic Market By Region, 2026 - 2033, (US$ Billion)
- Introduction
- Market Share Analysis, By Region, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, For Regions, 2022-2033
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Therapy Type, en2026-2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Administration Route, 2026 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Patient Demographics, 2026 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2026 - 2033, (US$ Billion)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Therapy Type, 2026 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Administration Route, 2026 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Patient Demographics, 2026 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2026 - 2033, (US$ Billion)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Therapy Type, 2026 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Administration Route, 2026 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Patient Demographics, 2026 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2026 - 2033, (US$ Billion)
- U.K.
- Germany
- Italy
- France
- Spain
- Russia
- Benelux
- Denmark
- Norway
- Sweden
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Therapy Type, 2026 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Administration Route, 2026 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Patient Demographics, 2026 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2026 - 2033, (US$ Billion)
- China
- Taiwan
- India
- Japan
- Indonesia
- Malaysia
- Philippines
- Singapore
- Australia
- South Korea
- Rest of Asia Pacific
- Middle East & Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Therapy Type, 2026 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Administration Route, 2026 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Patient Demographics, 2026 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2026 - 2033, (US$ Billion)
- Bahrain
- Kuwait
- Oman
- Qatar
- Saudi Arabia
- UAE
- Israel
- South Africa
- North Africa
- Central Africa
- Rest of the Middle East
1. Competitive Landscape
- Pfizer Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Otsuka Pharmaceutical Co., Ltd.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Johnson & Johnson
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Sunovion Pharmaceuticals Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Novartis AG
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- H. Lundbeck A/S
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Recordati S.p.A.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Mylan N.V.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Alkermes plc
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Takeda Pharmaceutical Company Limited.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Acadia Pharmaceuticals Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
2. Section
- Research Methodology
- About Us
